Anika to Showcase Commercial and Pipeline Portfolio at 2019 AAOS Annual Meeting
March 11 2019 - 4:05PM
Business Wire
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated
orthopedics and regenerative medicines company specializing in
therapeutics based on its proprietary hyaluronic acid ("HA")
technology, today announced plans to showcase its innovative
commercial and pipeline portfolio at the upcoming American Academy
of Orthopedic Surgeons (AAOS) Annual Meeting, March 12-16 in Las
Vegas, Nevada. Anika will be exhibiting its injectable, HA-based,
surgical bone repair therapy in addition to its viscosupplement
(CINGAL) and cartilage repair (HYALOFAST) solutions.
“We’re excited to preview our bone repair therapy at the 2019
AAOS Annual Meeting, the largest gathering of orthopedic surgery
professionals from around the world,” said Joseph Darling,
President and CEO, Anika Therapeutics. “Our bone repair therapy,
which we plan to launch in the U.S. using our hybrid commercial
model in the second half of 2019, represents a major advance in the
surgical treatment of bone defects and marks an important milestone
in the progress of our regenerative medicine pipeline as it will be
our first internally developed surgical therapy to launch in the
U.S. We look forward to educating the orthopedic surgical community
at AAOS on the application and clinical advantages of this
innovative new treatment, as well as our broader orthopedic
medicine portfolio.”
Below are highlights of Anika’s planned activities:
- AAOS Annual Meeting – Booth 2570 –
March 13 – 15, 2019
Darling added, “Our participation in the 2019 AAOS Annual
Meeting represents an important opportunity for Anika to continue
building relationships with and gaining clinical insights from U.S.
orthopedic medicine thought-leaders who will be critical to the
success of our hybrid commercialization model and adoption of our
newly introduced treatments.”
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global,
integrated orthopedic and regenerative medicines company based
in Bedford, Massachusetts. Anika is committed to improving the
lives of patients with degenerative orthopedic diseases and
traumatic conditions with clinically meaningful therapies along the
continuum of care, from palliative pain management to regenerative
tissue repair. The Company has over two decades of global expertise
developing, manufacturing, and commercializing more than 20
products based on its proprietary hyaluronic acid (HA)
technology. Anika's orthopedic medicine portfolio
includes ORTHOVISC®, MONOVISC®,
and CINGAL®, which alleviate pain and restore
joint function by replenishing depleted HA,
and HYALOFAST, a solid HA-based scaffold to aid
cartilage repair and regeneration. For more information about
Anika, please visit www.anikatherapeutics.com.
Forward-Looking Statements
The statements made in the second sentence of the second
paragraph of this press release, which are not statements of
historical fact, are forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended.
These statements include, but are not limited to, those relating to
the Company’s U.S. commercial efforts with respect to its bone
repair therapy. These statements are based upon the current beliefs
and expectations of the Company’s management and are subject to
significant risks, uncertainties, and other factors. The Company’s
actual results could differ materially from any anticipated future
results, performance, or achievements described in the
forward-looking statements as a result of a number of factors
including, but not limited to, (i) the Company’s ability to
successfully commence and/or complete clinical trials of its
products on a timely basis or at all; (ii) the Company’s ability to
obtain pre-clinical or clinical data to support domestic and
international pre-market approval applications, 510(k)
applications, or new drug applications, or to timely file and
receive FDA or other regulatory approvals or clearances of its
products; (iii) that such approvals will not be obtained in a
timely manner or without the need for additional clinical trials,
other testing or regulatory submissions, as applicable; (iv) the
Company’s research and product development efforts and their
relative success, including whether we have any meaningful sales of
any new products resulting from such efforts; (v) the cost
effectiveness and efficiency of the Company’s clinical studies,
manufacturing operations, and production planning; (vi) the
strength of the economies in which the Company operates or will be
operating, as well as the political stability of any of those
geographic areas; (vii) future determinations by the Company to
allocate resources to products and in directions not presently
contemplated; (viii) the Company’s ability to successfully
commercialize its products, in the U.S. and abroad; (ix) quarterly
sales volume variation experienced by the Company, which can make
future results difficult to predict and period-to-period
comparisons potentially less meaningful; (x) the Company’s ability
to provide an adequate and timely supply of its products to its
customers; and (xi) the Company’s ability to achieve its growth
targets. Additional factors and risks are described in the
Company’s periodic reports filed with the Securities and Exchange
Commission, and they are available on the SEC’s website at
www.sec.gov. Forward-looking statements are made based on
information available to the Company on the date of this press
release, and the Company assumes no obligation to update the
information contained in this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190311005004/en/
For Investor Inquiries:Anika Therapeutics, Inc.Sylvia Cheung,
781-457-9000Chief Financial OfficerFor Media Inquiries:W2O
GroupSonal Vasudev, 917-523-1418sonal@w2ogroup.com
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Apr 2023 to Apr 2024